Literature DB >> 16631456

Managing complications of androgen deprivation therapy for prostate cancer.

Jeffrey M Holzbeierlein1.   

Abstract

With the increase in the number of prostate cancer cases seen in the United States, the use of androgen deprivation therapy (ADT) as a form of treatment has continued to rise. With the increasing use of ADT, it is important for the urologist to recognize the potential side effects from the use of ADT and ways in which to minimize or eliminate the risks from these side effects. This article describes the potential complications of ADT and the recommendations for treatment or prevention of these complications. In addition,we examine the role of nontraditional forms of ADT and the potential benefits they offer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631456     DOI: 10.1016/j.ucl.2005.12.008

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  12 in total

1.  [Social medicine assessment of patients with prostate cancer].

Authors:  W Hoffmann; W Vahlensieck; D-H Zermann
Journal:  Urologe A       Date:  2016-11       Impact factor: 0.639

2.  A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Authors:  Joshua M Lang; Marianne Wallace; Jordan T Becker; Jens C Eickhoff; Bjoern Buehring; Neil Binkley; Mary Jane Staab; George Wilding; Glenn Liu; Miroslav Malkovsky; Douglas G McNeel
Journal:  Clin Genitourin Cancer       Date:  2013-07-05       Impact factor: 2.872

3.  Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study.

Authors:  Narhari Timilshina; Shabbir Hussain; Henriette Breunis; Shabbir M H Alibhai
Journal:  Support Care Cancer       Date:  2010-10-16       Impact factor: 3.603

Review 4.  Management of complications of androgen deprivation therapy in the older man.

Authors:  Supriya G Mohile; Karen Mustian; Kathryn Bylow; William Hall; William Dale
Journal:  Crit Rev Oncol Hematol       Date:  2008-10-25       Impact factor: 6.312

5.  Estrogenic side effects of androgen deprivation therapy.

Authors:  Theresa A Guise; Michael G Oefelein; James A Eastham; Michael S Cookson; Celestia S Higano; Matthew Raymond Smith
Journal:  Rev Urol       Date:  2007

6.  Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.

Authors:  M D Krahn; K E Bremner; J Luo; S M H Alibhai
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

7.  Penile Rehabilitation Strategies Among Prostate Cancer Survivors.

Authors:  Fouad Aoun; Alexandre Peltier; Roland van Velthoven
Journal:  Rev Urol       Date:  2015

8.  Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art.

Authors:  Piotr Milecki; Piotr Martenka; Andrzej Antczak; Zbigniew Kwias
Journal:  Cancer Manag Res       Date:  2010-10-11       Impact factor: 3.989

9.  Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues.

Authors:  Aditya Bagrodia; Christopher J Diblasio; Robert W Wake; Ithaar H Derweesh
Journal:  Indian J Urol       Date:  2009-04

10.  The side effects of hormonal therapy at the patients with prostate cancer.

Authors:  Ewa Ziółkowska; Małgorzata Zarzycka; Tomasz Wiśniewski; Agnieszka Zyromska
Journal:  Contemp Oncol (Pozn)       Date:  2013-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.